BUY PANTECH for a potential 62% upside to TP of RM0.88. PANTECH is a One-Stop Centre for pipes, fittings, flanges, valves, and other components providing total solutions for gas and fluid transmission system for the O
Bonus issue of up to 346,101,887 free warrants ("Warrants") on the basis of 3 Warrants for every 10 existing ordinary shares in Scope Industries Berhad held as at 5.00 p.m. on 23 November 2021 ("Entitlement Date") ("Bonus Issue of Warrants")
Kindly be advised of the following : 1) The above Company’s securities will be traded and quoted “EX-BONUS ISSUE” as from: 22 Nov 2021 2) The last date of lodgment : 23 Nov 2021
No two companies are alike; just as no two people are the same - not even twins. Yes, Hong Seng is definitely "unique". But what matters, and I can only speak for myself, is that this company's shares have given me a profit of more than RM100,000 in just over 3 months. Admittedly as a small investor, I've never made so much money in such a short period of time. This is on top of the RM50,000 I made on shares that I bought in 2015 (when the company was known as Panpages) that grew in value from bonuses and splits after Hong Seng came into the picture. Maybe I can count my lucky stars.
Katanya, jumlah dos yang diperlukan bagi vaksinasi di Malaysia pada 2022 diunjurkan RM10 bilion dan kumpulan menyasarkan memperoleh 10 hingga 20 peratus daripada jumlah itu.
"Itu sasarannya, tetapi sudah tentu kami menyasarkan penguasaan pasaran yang lebih tinggi. Ini kerana, Immunize adalah platform menyeluruh dan memberi kemudahan kepada rakyat berbanding platform vaksinasi swasta yang lain.
"Kami mempunyai teknologi, rangkaian lebih 8,000 klinik di bawah anak syarikat Hong Seng, eMedAsia Sdn Bhd serta jalinan kerjasama dengan rakan berkepentingan yang lain.
The recent price rise seems to suggest that the coming QR result expected on Oct 26 is good. Also the buoyancy in oil and gas, and steel prices augurs well for Pantech which manufactures and supplies its products to the oil and gas, manufacturing and construction industries.
Muar Ban Lee plans private placement to raise up to RM25.69m to repay bank borrowings KUALA LUMPUR (Oct 5): Muar Ban Lee Group Bhd (MBL) has proposed to undertake a private placement of up to 20% of its total number of issued shares to raise up to RM25.69 million to repay bank borrowings. MBL said in a bourse filing the proposed exercise will involve the issuance of up to 58.85 million shares to investors at an issue price to be determined. The expected proceeds raised are based on an illustrative issue price of 43.66 sen per placement share.
From Rakuten Trade's Research Hive: Omesti Bhd (Fundamental BUY with TP 0.71)
Omesti Bhd (Omesti) is primarily involved in providing network connectivity and bandwidth services, and project management services in relation to telecommunications via its 51.8% subsidiary Microlink Bhd.
On 27 July 2021, the company acquired a 70% stake in Bemed Tempua Sdn. Bhd. (Bemed Tempua) for RM700,000 and is now a Covid-19 vaccine provider for the private sector.
Omesti jumped into the Covid-19 vaccine bandwagon and launched the Omesti Healthcare Vaccin8 Programme (“Healthcare Programme”) providing vaccination services to companies for their employees as part of the nationwide drive to achieve herd immunity status.
Authorised by the Jawatankuasa Khas Jaminan Akses Bekalan Vaksin COVID-19 (JKJAV) and the Ministry of Health Malaysia (MOH), the 1m doses of Sinovac vaccines acquired from Pharmaniaga enables Omesti to execute its Healthcare Programme. In addition, Omesti is also providing Oral Fluid Antigen Test Kit (approved by the MOH) to existing clients and via online marketing. Demand for its vaccines and test kits remains resilient as the company has already secured substantial orders from companies across different sectors.
Balance sheet is healthy with net cash position of RM27.7m as at FY21.
This new source of income will greatly enhance Omesti’s earnings for FY22 and beyond. BUY with a target price of RM0.71 based on sum of parts valuation, implying a forward PER of 16.5x for FY22. Our BUY recommendation is premised on: (i) strong sales achieved since the launch of Healthcare Programme; (ii) orders secured from the private sectors providing recurring earnings; and (iii) healthy profit margins going forward.